Plus Therapeutics Expands CNSide Diagnostic Capabilities
HOUSTON — CNSide Diagnostics, LLC, a completely owned subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), is excited to announce the expansion of its CNSide testing platform with the recent acquisition of lab licenses to offer its innovative Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) test in additional states, including California, Rhode Island, and Maryland.
Enhancing Patient Care for CNS Cancers
With these new licenses, CNSide Diagnostics is now authorized to provide its specialized testing services in 48 out of 50 states across the U.S. This strategic expansion is crucial for the organization, as it aspires to deliver the advantages of CNSide CSF testing to the broadest range of patients diagnosed with central nervous system (CNS) cancers. Russ Bradley, President and General Manager of CNSide Diagnostics, expressed enthusiasm about this development, highlighting the broader access it creates for patients.
Bradley stated, "Obtaining these state licenses is a vital enabler of our plan to connect with more patients and health care providers. We are committed to executing our U.S. market access strategy and plan to continue expanding our test coverage and partnerships with payors and state health authorities."
Benefits of the CNSide CSF Assay Platform
The CNSide CSF Assay Platform is designed to facilitate rapid diagnostics, treatment monitoring, and treatment guidance for individuals dealing with leptomeningeal metastases. Compared to standard care, CNSide has demonstrated superior clinical utility, supported by nine peer-reviewed publications and its validation in the real-world setting through the FORESEE clinical trial.
Since its inception in 2020, CNSide Diagnostics has completed over 11,000 tests in more than 120 cancer institutions in the U.S., achieving a high sensitivity of 92% and a specificity rate of 95%. Notably, the results from these tests have influenced treatment decisions in 90% of the cases.
A Commitment to Quality and Efficiency
The CNSide® test is offered exclusively through CNSide Diagnostics, LLC, facilitating healthcare professionals across the U.S. with essential resources for diagnosing and managing patients with CNS cancers. The tests are processed in their CLIA-certified facility located in Houston, Texas, underscoring their commitment to quality and regulatory compliance.
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC focuses on developing and commercializing proprietary lab-developed tests like CNSide®, which aim to identify tumor cells metastasized to the central nervous system in carcinoma and melanoma patients. The CNSide® CSF Assay Platform provides a quantitative analysis of cerebrospinal fluid, greatly enhancing patient management strategies.
About Plus Therapeutics
Plus Therapeutics, Inc. is a visionary clinical-stage pharmaceutical company headquartered in Houston, Texas. It specializes in creating targeted radiotherapeutics aimed at challenging cancers, particularly those affecting the central nervous system. With leading programs focused on leptomeningeal metastases and recurrent glioblastoma, Plus Therapeutics utilizes innovative approaches combining image-guided local beta radiation with targeted drug delivery. The company continues to cultivate strategic partnerships that enhance the development and potential commercialization of its advanced therapies.
Frequently Asked Questions
What is the CNSide assay testing platform?
The CNSide assay testing platform is designed to provide critical diagnostics and treatment guidance for patients with CNS cancers by analyzing cerebrospinal fluid for tumor cells.
What states can benefit from Plus Therapeutics' expanded services?
With the recent expansion, CNSide Diagnostics can now serve patients in California, Rhode Island, and Maryland, among 45 other states.
How effective is the CNSide CSF test?
The CNSide CSF assay test has demonstrated a sensitivity rate of 92% and specificity rate of 95%, providing reliable diagnostic support.
Who can access the CNSide testing services?
The CNSide testing services are available exclusively to healthcare professionals in the U.S.
How does Plus Therapeutics ensure the quality of its tests?
Plus Therapeutics ensures quality through its CLIA-certified laboratory facility where all tests are conducted under stringent regulatory standards.
